
|Videos|November 4, 2015
How Have High Cost Hepatitis C Drugs Impacted Specialty Pharmacy?
Author(s)Davy James, Managing Editor
Ryan Nolan, PharmD, MBA, CSP, clinical services manager at Diplomat, discusses ongoing lessons from the market reaction to high cost hepatitis C treatments.
Advertisement
Ryan Nolan, PharmD, MBA, CSP, clinical services manager at Diplomat, discusses ongoing lessons from the market reaction to high cost hepatitis C treatments.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First-in-Class Daraxonrasib for Metastatic Pancreatic Cancer
2
Yeast-Based Universal Flu Vaccine Fully Protects Mice Against 3 Influenza Strains
3
FDA Grants Fast Track Designation to CK0803 for Amyotrophic Lateral Sclerosis
4
Pharmacists' Expanding Role in MASLD Screening and Care
5


































































































